Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New device aims to prevent vaginal scarring after cancer radiation

NCT ID NCT07473271

Disease control Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a special device that combines a vaginal dilator with a drug delivery tube to help prevent vaginal narrowing and scarring after pelvic radiation therapy. About 76 women aged 18-70 who have completed radiation for pelvic tumors will use the device regularly. The goal is to see if it reduces vaginal side effects and improves quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 76 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. women aged 18 to 70 years. 2. After radiotherapy for pelvic tumors, the tumor is well controlled (no macroscopically visible tumor). At least 1 week after radiotherapy, regular vaginal dilation and irrigation are expected to be performed subsequently. 3. ECOG 0-2. 4. prospected survival greater than 6 months. 5. Good communication skills, no history of mental illness. 6. Consent to participate in this trial and voluntarily sign the informed consent form. Exclusion Criteria: 1. Malignant tumors in other parts of the body. 2. congenital vaginal stenosis or pre-enrollment confirmed vaginal stenosis. 3. Allergic to silica gel and polyvinyl chloride materials. 4. active vaginal bleeding. 5. It is anticipated that cooperation with the treatment will not be possible. 6. The disease may cause difficulties in treatment and evaluation (e.g., sepsis, inability of the patient to tolerate treatment, etc.). 7. pregnant and lactating women. 8. Participated in other clinical trials involving drugs or medical devices within the past 3 months. 9. The investigators consider other conditions unsuitable for participation in this trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cervical carcinoma endometrial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Indicated for pelvic radiotherapy, vaginal rehabilitation, and alleviation of late toxic reactions in the vagina

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.